Zeo ScientifiX Reports 19.7% Revenue Growth but Increases Net Loss in Latest Quarter

Zeo ScientifiX, Inc. reported a revenue increase of 19.7% for the three months ending July 31, 2025, generating $1.306 million compared to $1.091 million in the same period last year. For the nine-month period, revenues rose by 5.0% to $3.545 million from $3.376 million. The growth in revenue was primarily attributed to increased sales from the Company’s PPX™ service platform, which saw a significant uptick in customer engagement, although this was partially offset by a decline in sales of allogenic aesthetic biologic products. The gross profit for the quarter was $1.078 million, representing 82.5% of revenues, while the nine-month gross profit was $2.870 million, or 81.0% of revenues.

Despite the revenue growth, Zeo ScientifiX reported a net loss of $2.072 million for the quarter, compared to a loss of $1.012 million in the same period last year. For the nine months, the net loss was $4.706 million, up from $3.451 million in the prior year. The increase in losses was largely due to a 51% rise in general and administrative expenses, which reached $3.149 million for the quarter, driven by higher stock-based compensation and professional fees. The Company’s accumulated deficit also widened to $66.919 million as of July 31, 2025.

Operationally, Zeo ScientifiX has made strategic moves, including the acquisition of BioLumina assets for $200,000, which included inventory and intellectual property. The Company has also entered into a joint venture with BioXtek, aiming to enhance its product offerings in the wound care and surgical markets. However, the Company faces challenges, including a stockholders' deficit of $2.314 million and ongoing concerns regarding its ability to comply with FDA regulations, which could impact its product sales.

As of July 31, 2025, Zeo ScientifiX had cash reserves of $314,000, down from $657,000 at the end of the previous fiscal year. The Company utilized $335,000 in operating activities during the nine months, a decrease from $1.084 million in the same period last year, indicating improved cash management. However, the Company remains dependent on external financing to sustain operations and fund ongoing research and development. Management has expressed substantial doubt about the Company’s ability to continue as a going concern without additional capital, highlighting the need for strategic financial planning moving forward.